D
Deleted member 410329
Platinum
- Joined
- Apr 26, 2026
- Posts
- 1,158
- Reputation
- 449
high effort post even though it only took two days. It was hell researching ts. Anyways enjoy and rep
being short sucks in this game. you can have a decent face and decent muscle but if you’re 5’6” or under you still get mogged hard in certain situations. most heightmaxxing threads are full of the same old stuff that gives minimal results once you’re past mid-teens. some guys are now talking about targeting the actual brake on bone growth , fgfr3.
tyra-300, also called dabogratinib, is an oral, highly selective fgfr3 inhibitor from tyra biosciences. it’s designed to block mainly fgfr3 (the receptor that slows down cartilage proliferation in your growth plates) while leaving fgfr1, 2 and 4 mostly untouched. that selectivity is the main reason it’s getting attention over older pan-fgfr inhibitors like infigratinib.
i went through the jci insight 2025 paper and the beach301 phase 2 trial updates. this thread is long because i want to lay it all out properly mechanism, the actual mouse data with numbers, how it compares, trial dosages, hypothetical research chem use, risks, and the cold truth about whether it’s worth gambling on.
first and most important blackpill
if your growth plates are fused (get a real left hand/wrist bone age x-ray from a doctor), this compound will not make you taller vertically. it might affect bone thickness or other tissues but the window for adding length to long bones is closed. only worth considering if you’re young enough (roughly under 18-20) and imaging still shows clear open plates with growth potential left.
why fgfr3 is the key target
fgfr3 acts as a negative regulator in the growth plates. it tells chondrocytes (cartilage cells) to slow down so you don’t grow infinitely. in achondroplasia there’s a gain-of-function mutation that makes fgfr3 overactive, leading to very short limbs. even in normal short guys, fgfr3 puts a limit on how much your bones can lengthen before they ossify and close.
by selectively inhibiting fgfr3 you lift that brake. this allows more chondrocyte proliferation and better differentiation in the hypertrophic zone of the growth plate → potentially longer bones while the plates are still open.
tyra-300 was made using their snap platform to be isoform-selective for fgfr3. in vitro data shows it has much higher selectivity over other fgfrs compared to pan-inhibitors. that means less of the classic off-target sides that forced dose reductions or stops in older compounds.
preclinical data - the numbers that actually matter
the 2025 jci insight study tested tyra-300 in three different models: wild-type (normal) mice, achondroplasia model (fgfr3 y367c/+), and hypochondroplasia model (fgfr3 n534k/+).
in wild-type mice: treatment led to dose-dependent increases in naso-anal length, tibia length and femur length. this is key because it shows the compound can push growth even without a mutation.
in the achondroplasia model: daily 1.2 mg/kg subcutaneous for 15 days starting from day 1 of life gave:
• naso-anal length +17.88%
• tail length +25.10%
• tibia +33.01%
• femur +22.55%
• ulna +23.51%
• humerus +15.52%
body weight also increased significantly (+52.9%). importantly, it preferentially lengthened the disproportionately short bones, helping restore better overall proportions. histology showed improved chondrocyte organization, more proliferation and better differentiation in the growth plate. it also improved foramen magnum size (skull base), which is relevant for avoiding some ach-related complications.
in the hypochondroplasia model: 1.8 mg/kg daily for 21 days starting day 3:
• femur +3.70%
• tibia +3.75%
• humerus +3.22%
• ulna +5.03%
the percentage gains look smaller than in the ach model because the phenotype is milder and the growth window is different, but it still moved the bones toward wild-type proportions (average ~25% normalization).
compared to low-dose infigratinib in the same models, tyra-300 showed stronger bone length increases at the tested doses while being more selective. it also improved vertebral bodies and skull base in some cases.
these are not tiny changes especially the ach model results are impressive for a short treatment period early in life. the mechanism is direct: it modulates the growth plate to allow more cartilage expansion before ossification.
current clinical status (as of april 2026)
the beach301 phase 2 trial is ongoing in kids aged 3-10 with achondroplasia and confirmed open growth plates. it’s an open-label dose-escalation/expansion study. doses being tested: 0.125, 0.25, 0.375, and 0.50 mg/kg once daily (weight-based, adjusted every 3 months). they use sprinkle capsules.
first child was dosed in august 2025. the safety sentinel cohort has cleared early dose levels with no major red flags reported so far. interim safety and 6-month height velocity data are expected in the second half of 2026. the trial will also look at height z-score, proportionality, and pharmacokinetics.
no public human height velocity data in normal short stature kids yet everything is still early and focused on achondroplasia. it has orphan drug and rare pediatric disease designations from fda.
dosages – what we know and what people are guessing
in the beach301 trial they use weight-based dosing from 0.125 mg/kg up to 0.50 mg/kg once daily. for a 60-70 kg teenager that would roughly translate to 7.5-35 mg per day, but that’s not exact because the trial is in younger kids and doses get adjusted.
preclinical mouse doses were higher (1.2 mg/kg in ach model, 1.8 mg/kg in hch model, up to 12-14 mg/kg in some wild-type experiments), but human equivalent doses are always lower due to metabolism differences.
on underground research chem sites you’ll see people throwing around 10-30 mg daily or even higher. some talk about starting at 10 mg and titrating based on bloodwork. there is zero established protocol for healthy short guys this is completely experimental territory.
if anyone is thinking about it, the smart move is start low, go slow, and monitor phosphate, calcium, liver/kidney function, eye exams, and growth velocity with regular x-rays. guessing high doses because “more inhibition = more growth” is how you invite serious problems.
risks – read this twice
even with good selectivity, fgfr inhibitors are not harmless. possible sides include:
• hyperphosphatemia (elevated phosphate levels) usually milder than with pan-fgfr drugs but still needs monitoring and possible diet or med adjustments
• eye problems (dry eyes, corneal issues) regular ophthalmology checks are recommended tbh
• gastrointestinal issues like diarrhea or stomatitis (mouth sores)
• nail and skin changes
• slipped capital femoral epiphysis (hip problem reported with other fgfr inhibitors in kids — on-target effect in growing bones)
• potential long-term unknowns: effects on bone density later, fertility, or any increased cancer risk down the line?
sourcing from research chem vendors means purity and actual content are a gamble. underdosed, overdosed or contaminated product is common.
running androgens, sarms or high-dose gear at the same time is stupid for heightmaxxing they can accelerate estrogen-mediated plate closure or speed up bone maturation, slamming the door shut early.
without full baseline bloodwork, monthly monitoring, bone age imaging, and eye exams you’re basically flying blind. this isn’t like running basic test or mk stuff.
and yeah, if you’re already sitting there thinking “but what about the sides bro” then maybe you don’t want it enough. real heightmaxxing at this level requires accepting calculated risk when the potential reward is meaningful extra cm before plates fuse. but don’t cope yourself into thinking it’s risk-free.
how it could fit into a serious stack (with heavy warnings)
theoretically, tyra-300 could be combined with things that push growth signals while plates are open — like pharma hgh (to raise igf-1) and very low-dose ai to slightly delay closure without crashing estrogen toohard.
but stacking randomly with high-dose anabolics or sarms is counterproductive — you risk faster maturation. the goal is to extend the open-plate window and maximize growth inside it, not close it early for temporary muscle gains.
no real human stack protocols exist yet. anyone claiming they have a “perfect tyra + hgh cycle” is probably bullshitting or gambling hard.
bottom line – no cope
tyra-300 looks like the cleanest fgfr3 inhibitor we’ve seen so far. the preclinical data is solid: clear, statistically significant increases in long bone length in both mutant and wild-type mice, better selectivity than infigratinib, improved growth plate histology, and some restoration of proportions. it’s oral once-daily, which is convenient.
if the phase 2 trial delivers good height velocity with acceptable safety later in 2026, it could become a real tool for open-plate heightmaxxing.
right now though it’s still experimental. hard to source reliably, no proven protocol for healthy teens, and real sides/risks exist.
get your bone age checked first. if plates still have good potential and you’re dead serious with money for monitoring, then research carefully. if they’re closing or already closed, shift focus to building the widest possible frame, losing fat for better proportions, and style/shoe lifts.
has anyone here messed with infigratinib or other fgfr stuff? what sides did you see
being short sucks in this game. you can have a decent face and decent muscle but if you’re 5’6” or under you still get mogged hard in certain situations. most heightmaxxing threads are full of the same old stuff that gives minimal results once you’re past mid-teens. some guys are now talking about targeting the actual brake on bone growth , fgfr3.
tyra-300, also called dabogratinib, is an oral, highly selective fgfr3 inhibitor from tyra biosciences. it’s designed to block mainly fgfr3 (the receptor that slows down cartilage proliferation in your growth plates) while leaving fgfr1, 2 and 4 mostly untouched. that selectivity is the main reason it’s getting attention over older pan-fgfr inhibitors like infigratinib.
i went through the jci insight 2025 paper and the beach301 phase 2 trial updates. this thread is long because i want to lay it all out properly mechanism, the actual mouse data with numbers, how it compares, trial dosages, hypothetical research chem use, risks, and the cold truth about whether it’s worth gambling on.
first and most important blackpill
if your growth plates are fused (get a real left hand/wrist bone age x-ray from a doctor), this compound will not make you taller vertically. it might affect bone thickness or other tissues but the window for adding length to long bones is closed. only worth considering if you’re young enough (roughly under 18-20) and imaging still shows clear open plates with growth potential left.
why fgfr3 is the key target
fgfr3 acts as a negative regulator in the growth plates. it tells chondrocytes (cartilage cells) to slow down so you don’t grow infinitely. in achondroplasia there’s a gain-of-function mutation that makes fgfr3 overactive, leading to very short limbs. even in normal short guys, fgfr3 puts a limit on how much your bones can lengthen before they ossify and close.
by selectively inhibiting fgfr3 you lift that brake. this allows more chondrocyte proliferation and better differentiation in the hypertrophic zone of the growth plate → potentially longer bones while the plates are still open.
tyra-300 was made using their snap platform to be isoform-selective for fgfr3. in vitro data shows it has much higher selectivity over other fgfrs compared to pan-inhibitors. that means less of the classic off-target sides that forced dose reductions or stops in older compounds.
preclinical data - the numbers that actually matter
the 2025 jci insight study tested tyra-300 in three different models: wild-type (normal) mice, achondroplasia model (fgfr3 y367c/+), and hypochondroplasia model (fgfr3 n534k/+).
in wild-type mice: treatment led to dose-dependent increases in naso-anal length, tibia length and femur length. this is key because it shows the compound can push growth even without a mutation.
in the achondroplasia model: daily 1.2 mg/kg subcutaneous for 15 days starting from day 1 of life gave:
• naso-anal length +17.88%
• tail length +25.10%
• tibia +33.01%
• femur +22.55%
• ulna +23.51%
• humerus +15.52%
body weight also increased significantly (+52.9%). importantly, it preferentially lengthened the disproportionately short bones, helping restore better overall proportions. histology showed improved chondrocyte organization, more proliferation and better differentiation in the growth plate. it also improved foramen magnum size (skull base), which is relevant for avoiding some ach-related complications.
in the hypochondroplasia model: 1.8 mg/kg daily for 21 days starting day 3:
• femur +3.70%
• tibia +3.75%
• humerus +3.22%
• ulna +5.03%
the percentage gains look smaller than in the ach model because the phenotype is milder and the growth window is different, but it still moved the bones toward wild-type proportions (average ~25% normalization).
compared to low-dose infigratinib in the same models, tyra-300 showed stronger bone length increases at the tested doses while being more selective. it also improved vertebral bodies and skull base in some cases.
these are not tiny changes especially the ach model results are impressive for a short treatment period early in life. the mechanism is direct: it modulates the growth plate to allow more cartilage expansion before ossification.
current clinical status (as of april 2026)
the beach301 phase 2 trial is ongoing in kids aged 3-10 with achondroplasia and confirmed open growth plates. it’s an open-label dose-escalation/expansion study. doses being tested: 0.125, 0.25, 0.375, and 0.50 mg/kg once daily (weight-based, adjusted every 3 months). they use sprinkle capsules.
first child was dosed in august 2025. the safety sentinel cohort has cleared early dose levels with no major red flags reported so far. interim safety and 6-month height velocity data are expected in the second half of 2026. the trial will also look at height z-score, proportionality, and pharmacokinetics.
no public human height velocity data in normal short stature kids yet everything is still early and focused on achondroplasia. it has orphan drug and rare pediatric disease designations from fda.
dosages – what we know and what people are guessing
in the beach301 trial they use weight-based dosing from 0.125 mg/kg up to 0.50 mg/kg once daily. for a 60-70 kg teenager that would roughly translate to 7.5-35 mg per day, but that’s not exact because the trial is in younger kids and doses get adjusted.
preclinical mouse doses were higher (1.2 mg/kg in ach model, 1.8 mg/kg in hch model, up to 12-14 mg/kg in some wild-type experiments), but human equivalent doses are always lower due to metabolism differences.
on underground research chem sites you’ll see people throwing around 10-30 mg daily or even higher. some talk about starting at 10 mg and titrating based on bloodwork. there is zero established protocol for healthy short guys this is completely experimental territory.
if anyone is thinking about it, the smart move is start low, go slow, and monitor phosphate, calcium, liver/kidney function, eye exams, and growth velocity with regular x-rays. guessing high doses because “more inhibition = more growth” is how you invite serious problems.
risks – read this twice
even with good selectivity, fgfr inhibitors are not harmless. possible sides include:
• hyperphosphatemia (elevated phosphate levels) usually milder than with pan-fgfr drugs but still needs monitoring and possible diet or med adjustments
• eye problems (dry eyes, corneal issues) regular ophthalmology checks are recommended tbh
• gastrointestinal issues like diarrhea or stomatitis (mouth sores)
• nail and skin changes
• slipped capital femoral epiphysis (hip problem reported with other fgfr inhibitors in kids — on-target effect in growing bones)
• potential long-term unknowns: effects on bone density later, fertility, or any increased cancer risk down the line?
sourcing from research chem vendors means purity and actual content are a gamble. underdosed, overdosed or contaminated product is common.
running androgens, sarms or high-dose gear at the same time is stupid for heightmaxxing they can accelerate estrogen-mediated plate closure or speed up bone maturation, slamming the door shut early.
without full baseline bloodwork, monthly monitoring, bone age imaging, and eye exams you’re basically flying blind. this isn’t like running basic test or mk stuff.
and yeah, if you’re already sitting there thinking “but what about the sides bro” then maybe you don’t want it enough. real heightmaxxing at this level requires accepting calculated risk when the potential reward is meaningful extra cm before plates fuse. but don’t cope yourself into thinking it’s risk-free.
how it could fit into a serious stack (with heavy warnings)
theoretically, tyra-300 could be combined with things that push growth signals while plates are open — like pharma hgh (to raise igf-1) and very low-dose ai to slightly delay closure without crashing estrogen toohard.
but stacking randomly with high-dose anabolics or sarms is counterproductive — you risk faster maturation. the goal is to extend the open-plate window and maximize growth inside it, not close it early for temporary muscle gains.
no real human stack protocols exist yet. anyone claiming they have a “perfect tyra + hgh cycle” is probably bullshitting or gambling hard.
bottom line – no cope
tyra-300 looks like the cleanest fgfr3 inhibitor we’ve seen so far. the preclinical data is solid: clear, statistically significant increases in long bone length in both mutant and wild-type mice, better selectivity than infigratinib, improved growth plate histology, and some restoration of proportions. it’s oral once-daily, which is convenient.
if the phase 2 trial delivers good height velocity with acceptable safety later in 2026, it could become a real tool for open-plate heightmaxxing.
right now though it’s still experimental. hard to source reliably, no proven protocol for healthy teens, and real sides/risks exist.
get your bone age checked first. if plates still have good potential and you’re dead serious with money for monitoring, then research carefully. if they’re closing or already closed, shift focus to building the widest possible frame, losing fat for better proportions, and style/shoe lifts.
has anyone here messed with infigratinib or other fgfr stuff? what sides did you see
